RecruitingNCT07595653

A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

Non-interventional, Longitudinal Hybrid Data Sources Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy

Sponsor

argenx

Enrollment

100 participants

Start Date

Feb 25, 2026

Study Type

OBSERVATIONAL

Conditions

Generalized Myasthenia Gravis (gMG)gMG

Summary

This study aims to generate real world evidence (RWE) from Italian clinical practice on the impact of efgartigimod alfa in gMG patients encompassing clinical outcomes and patient reported experiences. The study population will consist in adult patients with a documented diagnosis of gMG who are AChR-antibody positive and for whom the decision of treatment with efgartigimod alfa for gMG has been made independently of study participation as part of routine clinical care. The total study duration will be up to 23 months

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with generalized myasthenia gravis (gmg) and gmg. The study is currently recruiting participants at 30 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(30)

Ospedale Generale Regionale F. Miulli

Acquaviva delle Fonti, Italy

Azienda Ospedaliero Universitaria delle Marche

Ancona, Italy

A.O.U. Consorziale Policlinico

Bari, Italy

ASST Papa Giovanni XXIII

Bergamo, Italy

Ospedale Bellaria

Bologna, Italy

A.O.U. Renato Dulbecco

Catanzaro, Italy

A.O.U. Careggi

Florence, Italy

IRCCS Ospedale Policlinico San Martino

Genova, Italy

A.O.U. Policlinico G. Martino

Messina, Italy

IRCCS Cà Granda Ospedale Maggiore Policlinico

Milan, Italy

Ospedale San Raffaele

Milan, Italy

IRCCS Istituto Neurologico Carlo Besta

Milan, Italy

ASST GOM Niguarda

Milan, Italy

A.O.U. Policlinico Universitario

Monserrato, Italy

AORN A. Cardarelli

Naples, Italy

A.O.U. Università della Campania L. Vanvitelli

Naples, Italy

A.O.U. San Luigi Gonzaga

Orbassano, Italy

Azienda Ospedale Università Padova

Padova, Italy

IRCCS Fondazione Mondino

Pavia, Italy

Azienda Ospedaliera Perugia

Perugia, Italy

A.O.U. Pisana

Pisa, Italy

Ospedale degli Infermi

Rimini, Italy

Fondazione PTV Policlinico Tor Vergata

Roma, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Italy

Ospedale Sant'Andrea

Roma, Italy

A.O.U. San Giovanni di Dio e Ruggi D'Aragona

Salerno, Italy

IRCCS Fondazione Casa Sollievo della Sofferenza

San Giovanni Rotondo, Italy

A.O.U. Sassari

Sassari, Italy

Ospedale Ca' Foncello

Treviso, Italy

AOUI Verona - Policlinico G.B. Rossi

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07595653

Related Trials

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

NCT076736272 locations

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

NCT072472797 locations

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT0728442015 locations

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT0729417018 locations

Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT063126447 locations